Each vial contains: Cefuroxime (as Sodium) 750 mg.
Cefuroxime is an alternative drug for infections due to susceptible organisms such as in otitis media, orbital cellulitis, urinary tract, skin and soft tissue, bone & joint infections and post-splenectomy sepsis of unclear etiology.
Adults: 2-4 g/daily divided to 9 hours IV push over 3-5 min or IV infusion over 15-30 min.
NB: 50-100 mg/kg/daily divided to 12 hours IV push over 5 min or IV infusion over 15-30 min.
CH: 100-150 mg/kg/daily divided to 8 hours IV push over 3-5 min or IV infusion over 15-30 min, maximum dose: 6 g/daily.
Gonorrhoea: 1.5 g as a single dose (as 2 x 750 mg injections intramuscularly with different sites, e.g. each buttock).
Meningitis: Cefuroxime (as Sodium) 750 mg Powder for Injection is suitable for sole therapy of bacterial meningitis due to sensitive strains.
Adults: 3 g IV every 8 hours.
Infants and Children: 150-250 mg/kg/day IV in 3 or 4 divided doses.
Neonates: The dosage should be 100 mg/kg/day IV.
Prophylaxis: The usual dose is 1.5 g IV with induction of anaesthesia for abdominal, pelvic and orthopaedic operations. This may be supplemented with two 750 mg IM doses eight and sixteen hours later. In cardiac, pulmonary, oesophageal and vascular operations, the usual dose is 1.5 g IV with induction of anaesthesia, continuing with 750 mg IM three times daily, for a further 24 to 48 hours. In total joint replacement, 1.5 g Cefuroxime (as Sodium) Powder for Injection may be mixed dry with each pack of methyl methacrylate cement polymer before adding the liquid polymer.
Impaired Renal Function: Cefuroxime is excreted by the kidneys. Therefore, as with all such antibiotics, in patients with markedly impaired renal function, it is recommended that the dosage of Cefuroxime Sodium for Injection should be reduced to compensate for its slower excretion.
It is not necessary to reduce the standard dose (750 mg-1.5 g three times daily) until the creatinine clearance falls to 20 mL/min or below.
In adults with marked impairment (creatinine clearance 10-20 mL/min) 750 mg twice daily is recommended and with severe impairment (creatinine clearance <10 mL/min) 750 mg once daily is adequate.
For patients on haemodialysis a further 750 mg dose should be given IV or IM at the end of each dialysis. In addition to parenteral use, Cefuroxime can be incorporated into the peritoneal dialysis fluid (usually 250 mg for every 2 liters of dialysis fluid given intravenously).
For patients in renal failure on continuous arteriovenous haemodialysis or high-flux haemofiltration in intensive therapy units a suitable dosage is 750 mg twice daily. For low-flux haemofiltration follow the dosage recommended under Impaired Renal Function.
Hypersensitivity to cephalosporin antibiotics.
Special care is indicated in patients who have experienced an allergic reaction to penicillins or other beta-lactams.
Cephalosporin antibiotics at high dosage should be given with caution to patients receiving concurrent treatment with potent diuretics such as furosemide or aminoglycosides, as renal impairment has been reported with these combinations. Renal function should be monitored in these patients, the elderly, and those with pre-existing renal impairment.
There is no experimental evidence of embryopathic or teratogenic effects attributable to cefuroxime, but, as with all drugs, it should be administered with caution during the early months of pregnancy.
Adverse reactions to cefuroxime have occurred relatively infrequently and have been generally mild and transient in nature.
There have been rare reports of hypersensitivity reactions including skin rashes, urticaria, pruritus, interstitial nephritis, drug fever and very rarely anaphylaxis.
Gastrointestinal disturbances, including, very rarely, symptoms of pseudomembranous colitis may occur during or after treatment; dizziness, headache, fatigue, fever.
Transient neutropenia, eosinophilia, hypoprothrombinemia, platelet dysfunction, haemolytic anemia.
Transient elevation of liver enzymes.
Cefuroxime does not interfere with enzyme-based tests for glycosuria.
Slight interference with copper reduction methods (Benedict's, Fehling's, Clinitest) may be observed. However, this should not lead to false-positive results, as may be experienced with some other cephalosporins.
Direction for Reconstitution: Intramuscular: Add 3 mL Water for Injections to Cefuroxime (as Sodium) 750 mg Powder for Injection. Shake gently to produce an opaque suspension.
Intravenous: Dissolve Cefuroxime (as Sodium) 750 mg Powder for Injection in at least 6 mL Water for Injections.
Intravenous infusion: These solutions may be given directly into the vein or introduced into the tubing of the giving set if the patient is receiving parenteral fluids.
Store at temperatures not exceeding 30°C.
Store in a cool dry place, protect from light.
Solution should be used within 5 hours of preparation if stored at a temperature below 20°C or within 48 hours if stored between 2°C to 8°C.
J01DC02 - cefuroxime ; Belongs to the class of second-generation cephalosporins. Used in the systemic treatment of infections.
Powd for inj (vial) 750 mg x 1's.